Table 2.
Patients and tumors baseline characteristics. All values are median (Q1–Q3) or number (percentage)
| All patients (n = 48) | Resin microspheres (n = 25) | Glass microspheres (n = 23) | p | |
|---|---|---|---|---|
| Age (y) | 66 (62–73) | 68 (63–74) | 64 (63–72) | NSa |
| Male gender | 42 (88) | 23 (92) | 19 (83) | NSb |
| Body surface area (m2) | 1.9 (1.8–2.0) | 1.9 (1.8–2.1) | 1.9 (1.7–2) | NSa |
| Cirrhosis | 37 (77) | 20 (80) | 16 (70) | NSb |
| Cause of cirrhosis | ||||
| Alcohol | 24 (65) | 14 (56) | 10 (43) | NSb |
| NASH | 10 (27) | 7 (28) | 4 (17) | NSb |
| HVC | 7 (19) | 4 (16) | 3 (13) | NSb |
| HBV | 2 (5) | 2 (8) | 0 (0) | NSb |
| Hemochromatosis | 2 (5) | 0 (0) | 2 (9) | NSb |
| Child–Pugh | ||||
| A5/A6 | 34 (92) | 18 (72) | 16 (70) | NSb |
| B7 | 3 (8) | 2 (8) | 1 (4) | NSb |
| MRI-based Liver volume (ml) | 1813 (1468–2358) | 1912 (1505–2308) | 1800 (1436–2435) | NSa |
| MRI-based Tumor volume (ml) | 203 (67–545) | 188 (68–312) | 284 (61–738) | NSa |
| SPECT threshold-based target volume (ml) | 360 (205–647) | 298 (202–406) | 593 (414–933) | 0.002a |
| PET threshold-based target volume (ml) | 386 (245–786) | 365 (214–643) | 398 (267–827) | NSa |
| Tumor burden (%) | 11 (5–27) | 8 (5–18) | 16 (5–34) | NSa |
| Injected activity (GBq) | 1.6 (1.1–2.6) | 1.3 (1.0–1.8) | 2.3 (1.4–3.3) | 0.004a |
NASH non-alcoholic steatohepatitis, HBV hepatitis B virus, HCV hepatitis C virus
aMann and Whitney test
bχ2 test